Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
The DOI matches its Crossref record; 158 of the 169 references it cites were found in a registry or an index.
Abstract
Objective: To update the "Testosterone Therapy in Men With Androgen Deficiency Syndromes" guideline published in 2010. Participants: The participants include an Endocrine Society-appointed task force of 10 medical content experts and a clinical practice guideline methodologist. Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation approach to describe the strength of recommendations and the quality of evidence. The task force commissioned two systematic reviews and used the best available evidence from other published systematic reviews and individual studies. Consensus Process: One group meeting, several conference calls, and e-mail communications facilitated consensus development. Endocrine Society committees and members and the cosponsoring organization were invited to review and comment on preliminary drafts of the guideline. Conclusions: We recommend making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone (T) deficiency and unequivocally and consistently low serum T concentrations. We recommend measuring fasting morning total T concentrations using an accurate and reliable assay as the initial diagnostic test. We recommend confirming the diagnosis by repeating the measurement of morning fasting total T concentrations. In men whose total T is near the lower limit of normal or who have a condition that alters sex hormone-binding globulin, we recommend obtaining a free T concentration using either equilibrium dialysis or estimating it using an accurate formula. In men determined to have androgen deficiency, we recommend additional diagnostic evaluation to ascertain the cause of androgen deficiency. We recommend T therapy for men with symptomatic T deficiency to induce and maintain secondary sex characteristics and correct symptoms of hypogonadism after discussing the potential benefits and risks of therapy and of monitoring therapy and involving the patient in decision making. We recommend against starting T therapy in patients who are planning fertility in the near term or have any of the following conditions: breast or prostate cancer, a palpable prostate nodule or induration, prostate-specific antigen level > 4 ng/mL, prostate-specific antigen > 3 ng/mL in men at increased risk of prostate cancer (e.g., African Americans and men with a first-degree relative with diagnosed prostate cancer) without further urological evaluation, elevated hematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, myocardial infarction or stroke within the last 6 months, or thrombophilia. We suggest that when clinicians institute T therapy, they aim at achieving T concentrations in the mid-normal range during treatment with any of the approved formulations, taking into consideration patient preference, pharmacokinetics, formulation-specific adverse effects, treatment burden, and cost. Clinicians should monitor men receiving T therapy using a standardized plan that includes: evaluating symptoms, adverse effects, and compliance; measuring serum T and hematocrit concentrations; and evaluating prostate cancer risk during the first year after initiating T therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TRT is also contra-indicated in people with (high risk of) prostate cancer, a history of breast cancer, thrombophilia, elevated hematocrit, untreated severe obstructive sleep apnea, uncontrolled heart failure, and myocardial infarction or stroke within the last 6 months [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It suppresses spermatogenesis, and thus, cannot be used in patients with a desire to have children in the near future.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It may result in gynecomastia, acne, testicular atrophy and erythrocytosis.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“The Endocrine Society guideline emphasizes the importance of lifestyle changes in men with central hypogonadism and comorbidities [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“Hyperprolactinemia also suppresses the secretion of GnRH and the response of gonadotropins to GnRH secretion.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Self-citationSex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846
Identification of late-onset hypogonadism in middle-aged and elderly men
Wu, F. C. W., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911101 · Cited by 1,544
Self-citationAdverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
Self-citationHeidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.11.002 · Cited by 1,341
Rosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1864 · Cited by 1,176 · cited 1×
“culated from TT, SHBG, and albumin levels (23, 24).”
Harrison's Principles of Internal Medicine
Massarelli, J. J. (1984) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1984.03340300091039 · Cited by 1,132
Research works printed but not linked: 1
- Bhasin, 2015, Disorders of the testes and male reproductive system
Cited by
Items 1,001–1,100 of 1,733
Thanaboonyawat, I., Chera-aree, P., Petyim, S., Choavaratana, R., & Laokirkkiat, P. (2020) · Clinical and Experimental Obstetrics & Gynecology · doi:10.31083/j.ceog.2020.06.5454 · Cited by 6
“It is a clinical syndrome with unequivocally and consistently low serum total T and/or free T concentrations [12].”
BackgroundTestosterone prescribing in men with depression and anxiety disorders
Javed, Z., Kuo, Y., Temple, J. R., Urban, R. J., Holmes, H. M., & Baillargeon, J. (2020) · Annals of Epidemiology · doi:10.1016/j.annepidem.2020.05.015 · Cited by 6
The Role of Testosterone Therapy in Men's Health
Smith, B. K., & Ward, M. P. (2023) · Nursing Clinics of North America · doi:10.1016/j.cnur.2023.07.001 · Cited by 4
Carlomagno, F., Tenuta, M., Sansone, A., Rastrelli, G., Sciarra, F., Cangiano, B., Isidori, A. M., Gianfrilli, D., & Krausz, C. G. (2026) · Human Reproduction Update · doi:10.1093/humupd/dmag010 · Cited by 3
“Other clinical features include small testicular volume, decreased body hair, gynaecomastia, and reduced shaving frequency, especially in those with profound testosterone deficiency (Bhasin et al. , 2018; Corona et al. , 2020b; Isidori et al. 2022).”
InfluentialClinical characteristics and comorbidities associated with testosterone prescribing in men
Sharma, A., Haq, Z. U., Sindi, E., Al‐Sharefi, A., Kamalati, T., Dhillo, W. S., Minhas, S., & Jayasena, C. N. (2021) · Clinical Endocrinology · doi:10.1111/cen.14643 · Cited by 2
“4% of men in Group A did not have repeat TT measurements despite index TT < 8 nmol/L and clinical guidelines suggesting two morning TT measurements in men for the diagnosis of hypogonadism.(7,9,14) In summary, it is plausible that some men are undertreated with TRT.”
BackgroundResultHendawy, L. (2020) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/syj9t · Cited by 2
Libman, H., Cohen, M. L., Irwig, M. S., & Smetana, G. W. (2021) · Annals of Internal Medicine · doi:10.7326/m21-2524 · Cited by 2
“Evidence has been inconclusive regarding its impact on cognitive function, mood, energy, and quality of life (3, 6, 11).”
BackgroundInfluentialSelim, S., Lona, H., Imran, S., Rahman, M., Mahjabeen, S., & Mustari, M. (2022) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_2_22 · Cited by 2
Sexual Function in Men and Women with Diabetes
Winkley, K., Kristensen, C. B., Fosbury, J., & Price, D. E. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch54 · Cited by 2
Male hypogonadism associated with obesity
Stárka, L., Dušková, M., & Hill, M. (2020) · Vnitřní lékařství · doi:10.36290/vnl.2020.154 · Cited by 3
“Diagnostika hypogonadismu u obézních O diagnostice i léčbě hypogonadismu existuje v literatuře řada dopo‐ ručení andrologických společností (1, 4) a návodů z poslední doby i v české literatuře (2, 6, 9, 12, 17, 21–24).”
Khan, M. Q., Hassan, S. M., Lizaola‐Mayo, B., Bhat, M., & Watt, K. D. S. (2023) · Hepatology · doi:10.1097/hep.0000000000000674 · Cited by 3
Efros, M. D., Kaminetsky, J. C., Sherman, N. D., Chan, A., & Thomas, J. W. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.05.015 · Cited by 2
Santi, D., Spaggiari, G., Furini, C., Griseta, V., Zizzi, E. A., Granata, A. R. M., & Simoni, M. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4838983 · Cited by 2
Jensterle, M., Janež, A., Vesnaver, T. V., Debeljak, M., Breznik, N., Podkrajšek, K. T., Herman, R., Fliers, E., Battelino, T., & Stefanija, M. A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1248231 · Cited by 2
Broul, M., Kelbich, P., Jizerová, A., Partlova, D., Hujová, A., & Liegertová, M. (2026) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2026.111148 · Cited by 2
Cheng, J. J., Shen, J., Suresh, Y., Akopyan, N. A., & Kapoor, N. S. (2024) · International Journal of Surgery Case Reports · doi:10.1016/j.ijscr.2024.110050 · Cited by 2
“For men with a history of prostate cancer, common practice is to avoid prescribing TRT due to concern for the risk of recurrence [2].”
BackgroundVold, J. H., Vogt, E., Heldal, A. T., Chalabianloo, F., Druckrey-Fiskaaen, K. T., Løberg, E., Methlie, P., Johansson, K. A., & Fadnes, L. T. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf114 · Cited by 1
“…OAT, where low testosterone levels are expected and concurrent clinical symptoms from other comorbid disorders may complicate the diagnostic assessment, knowledge of the thresholds for low testosterone levels using s-total testosterone and free testosterone according to guidelines [4] is essential.”
InfluentialWang, J., Zhou, Y., & He, L. (2022) · European Journal of Inflammation · doi:10.1177/1721727x221116739 · Cited by 2
“Testosterone replacement therapy has become a common treatment method for patients with testosterone deficiency, with a safety record and great efficacy.(12,24,25) However, other studies have shown that the abuse of testosterone replacement therapy may increase the incidence of cardiovascular events.”
BackgroundMethodTang, R., You, X., Yuan, B., Ling, Z., & Li, Y. (2025) · Medicine · doi:10.1097/md.0000000000044160 · Cited by 4
“[46] Males with T1D exhibiting high testosterone levels have demonstrated improved insulin sensitivity, [47] suggesting that testosterone’s beneficial effects in T1D may be partially attributed to enhanced metabolic mechanisms.”
Off-label testosterone therapy is associated with higher long-term cardiovascular risk in men
Kerniss, H., Curman, P., Olbrich, H., Kridin, K., Francis, R., Leistner, D. L. D. M., Alam, U., & Ludwig, R. J. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106373 · Cited by 2
“3–9 Despite the clear “on-label” and guideline-concordant framework, real-world TT use has expanded markedly over the past two decades, and prescribing patterns increasingly extend beyond classical organic hypogonadism.”
InfluentialImproving Outcomes and Preventing Complications in Cranial Base Surgery
Montano, N., Martinelli, R., & Almeida, J. P. (2024) · Brain Sciences · doi:10.3390/brainsci14111045 · Cited by 2
Grant, B., de Silva, N. L., Gumssani, M., Quinton, O., Kayali, F., Gamage, I., Dhillo, W. S., Grossmann, M., & Jayasena, C. N. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf689 · Cited by 3
Minuzzi, R. K., Petry, C., dos Santos, F. S., Semmelmann, A. L., Bassols, G. F., & Pereira‐Lima, J. F. S. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.04.005 · Cited by 3
Androgens and Parkinson’s disease: the role in humans and in experiment
Хамадьянова, А. У., Олегович, К. К., Gaifullina, E. I., Kalandin, D. A., Рафитовна, Х. Р., Khalitova, I. F., Faizov, R. M., Kamaletdinova, N. O., Aslanova, B. F., Nakieva, A. G., et al. (2022) · Problems of Endocrinology · doi:10.14341/probl13148 · Cited by 3
Protocolo diagnóstico del hipogonadismo en varones
Corrales, E. P., Castro, M. A., Ortiz-Flores, A. E., & Escobar-Morreale, H. F. (2020) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2020.09.006 · Cited by 2
Sardella, C., Urbani, C., Marconcini, G., Cappellani, D., Manetti, L., LIPERI, A. D., Romei, C., Morganti, R., Marcocci, C., & Bogazzi, F. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02148-7 · Cited by 2
“Moreover, our data suggest that hypogonadal acromegaly patients may be at high risk of fragility fractures and might benefit from bone active drugs [36].”
Braca, F., Betancort, J. C., Pérez‐Martín, N., Argany, Á. C., & Boronat, M. (2022) · Andrologia · doi:10.1111/and.14628 · Cited by 2
“He was then prescribed a starting low dose testosterone 2% gel of 20 mg/ day, lower than literature's recommended replacement adult dose (40–70 mg/day) (Bhasin et al., 2018), with the intention of promoting a progressive development of secondary sexual characteristics.”
BackgroundCardiovascular Safety of Testosterone-Replacement Therapy
Huang, Y., Shen, B., & Zhou, Y.-F. (2023) · New England Journal of Medicine · doi:10.1056/nejmc2309389 · Cited by 3
Testosterone and Cardiovascular Disease in Men
Zhao, D., & Guallar, E. (2021) · Annals of Internal Medicine · doi:10.7326/m21-4777 · Cited by 4
“In 2018, an Endocrine Society clinical practice guideline recommended against the initiation of testosterone therapy for men with chronic conditions, including uncontrolled heart failure, myocardial infarction, or stroke within the past 6 months—an attempt to further reduce potential cardiovascular risk related to tes…”
BackgroundMorbey, E. J., Day, F. R., Butterworth, A. S., Wareham, N. J., Perry, J. R. B., & Ong, K. K. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf582 · Cited by 3
“Evidence from randomised controlled trials (RCTs) shows beneficial effects of testosterone supplementation on sexual function, lean mass and muscle strength (3).”
Chawareb, E. A., Campos, L., Sávio, L. F., Hartman‐Kenzler, J., Mahdi, M., Hammad, M. A. M., & Yafi, F. A. (2025) · The Journal of Sexual Medicine · doi:10.1093/jsxmed/qdag118.345 · Cited by 3
Testosterone treatment and the risk of osteonecrosis: a pharmacovigilance analysis in Vigibase
Vabre, C., Johnson, K., Montastruc, F., Vezzosi, D., Yu, O. H. Y., & Renoux, C. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-022-03440-w · Cited by 2
An Interesting Presentation of Testosterone-Induced Arterial Thrombosis
Thompson, K., Osorio, L. G., Mughni, S., Jordan, J., & Oyesanmi, O. (2021) · Cureus · doi:10.7759/cureus.14972 · Cited by 2
“Testosterone therapy has been the mainstay of treatment for hypogonadism according to the Endocrine Society’s Clinical Practice Guidelines [1].”
MethodDefeudis, G., Maddaloni, E., Rossini, G., Tommaso, A. D. D., Mazzilli, R., Palma, P. D., Pozzilli, P., & Napoli, N. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11185333 · Cited by 3
“In case of diagnosis of ED (total score <22), patients were screened for hypogonadism, according to the criteria established by the Endocrine Society guidelines [23].”
MethodShores, M. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-54482-9_12 · Cited by 3
Xu, H., Zhang, H., Yang, R., Xie, X., Cao, Z., Zhao, Y. (., Lin, H., Lu, D., Bischoff, F. Z., Zhang, X., et al. (2026) · The Innovation Nutrition · doi:10.59717/j.xinn-nutri.2026.100004 · Cited by 2
Testosterone therapy is trending. Who really needs it, and why?
Lenharo, M. (2026) · Nature · doi:10.1038/d41586-026-01408-9 · Cited by 2
Management of Sexual Dysfunction
Rochira, V., Carani, C., & Granata, A. R. M. (2022) · doi:10.1093/med/9780198870197.003.0193 · Cited by 5
Management of Erythrocytosis in Men Receiving Testosterone Therapy: Clinical Consultation Guide
Agrawal, P. M., Singh, S. M., & Kohn, T. P. (2022) · European Urology Focus · doi:10.1016/j.euf.2022.10.008 · Cited by 2
Title: Updates on Testosterone Deficiency in Men Living With HIV and the Cardiovascular Implications
Garcia, M. L., Londono, V., & Martinez, C. A. (2024) · Current Infectious Disease Reports · doi:10.1007/s11908-024-00851-x · Cited by 2
“In men without HIV, the prevalence of biochemical male hypogonadism also increases with age, affecting approximately 12% of men aged 50 to 59 and rising to 49% in those aged 80 and older [3].”
Pruktanakul, T., Taemkaew, K., Liabsuetrakul, T., Leelawattana, R., & Kietsiriroje, N. (2020) · Journal of Health Science and Medical Research · doi:10.31584/jhsmr.2020766 · Cited by 2
“Journal of Health Science and Medical Research J Health Sci Med Res 2021;39(2):123-133 126 Results A total of 120 participants were stratified into three age groups, 18-29, 30-39, and 40-65 years, with 33, 49, and 38 participants, respectively.”
BackgroundInfluentialAnagnostis, P. G., Divaris, E., Zidrou, M., Kassi, E., & Tournis, S. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.108961 · Cited by 2
Gray, P. B., Meintjes, F. A., Moshokoa, E., & Mathabe, K. (2020) · The Aging Male · doi:10.1080/13685538.2020.1762075 · Cited by 2
Characterization of the secretory profile of gonadotroph pituitary tumors
Carretti, A. L., Ilie, M. D., Vasiljevic, A., et al. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02721-2 · Cited by 2
Najari, B. B. (2018) · PubMed Central · doi:10.3909/riu0814 · Cited by 2
Cerebral Venous Sinus Thrombosis: A Complication of Secondary Polycythemia From Testosterone Use
Pendyala, M., Saravanan, D. R., Kaur, P., Doddapaneni, V. K., & Wong, B. M. (2025) · Cureus · doi:10.7759/cureus.85789 · Cited by 2
“If no treatable cause is identified, phlebotomy can be considered [6].”
The endocrine manifestations of adults with spinal muscular atrophy
Rakuša, M., Koritnik, B., Leonardis, L., Goričar, K., Rudolf, T., Firbas, D., Snoj, Ž., & Jensterle, M. (2024) · Muscle & Nerve · doi:10.1002/mus.28275 · Cited by 3
Anabolic Steroid-Induced Hypogonadism
Hohl, A., Lee, S. V. D. S., & Ronsoni, M. F. (2023) · Springer eBooks · doi:10.1007/978-3-031-31501-5_12 · Cited by 5
Casals, G., Ferrer, R., Urgell, E., Escobar-Morreale, H. F., Argente, J., Sesmilo, G., & Biagetti, B. (2023) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2023.03.004 · Cited by 3
Monitoring of Testosterone Replacement Therapy to Optimize the Benefit-to-Risk Ratio
Hayes, F. J. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.11.013 · Cited by 4
Self-citationHamilton, B., Lima, G. H. O., Barrett, J., Seal, L., Kolliari-Turner, A., Guppy, F. M., & Pitsiladis, Y. P. (2021) · SportRxiv (OSF Preprints) · doi:10.31236/osf.io/4rc2b · Cited by 4
Improving the annual monitoring rates of testosterone replacement therapy patients in primary care
Hassoun, O., Starostka, M., Shearer, H. M., Millar, A., Hassoun, S. A., & Isles, C. (2022) · BMJ Open Quality · doi:10.1136/bmjoq-2021-001784 · Cited by 3
Testosterone Decreases Erythropoietin Stimulating Agent Use in Men on Hemodialysis
Dhindsa, S., Nargunan, V., Reddy, A., Clubb, C., Haider, A., Cheng, F., Prasad, V. H., & Dandona, P. (2020) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2020.0003 · Cited by 3
Gender-related response of body systems in COVID-19 affects outcome
Khaksari, M., Sabet, N., Soltani, Z., & Bashiri, H. (2021) · Russian Journal of Infection and Immunity · doi:10.15789/2220-7619-grr-1664 · Cited by 3
Shirai, M., Tsujimura, A., Mizushima, K., Tsuru, T., Kurosawa, M., Kure, A., Uesaka, Y., Nozaki, T., Kobayashi, K., & Horie, S. (2022) · Endocrine Journal · doi:10.1507/endocrj.ej22-0497 · Cited by 2
Glucocorticoid-induced osteoporosis in systemic lupus erythematosus
Phang, K. F., Cho, J., Lee, W., & Mak, A. (2018) · Rheumatology Practice and Research · doi:10.1177/2059902118802510 · Cited by 3
Thompson, L. V. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-88361-3_15 · Cited by 2
Winters, S. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-84367-0_30 · Cited by 2
Morgado, A., Moura, M. L., Dinis, P., & Silva, C. (2019) · International Journal of Impotence Research · doi:10.1038/s41443-019-0169-0 · Cited by 4
Soejima, Y., Otsuka, Y., Kawaguchi, M., Oguni, K., Yamamoto, K., Nakano, Y., Yasuda, M., Tokumasu, K., Ueda, K., Hasegawa, K., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062713 · Cited by 4
Reference Intervals of Total Testosterone in Adult Filipino Men
Buenaluz‐Sedurante, M., Co, M. I. K., Dagang, D. J., Bruno, R., Sarmiento, A. J., & Tee, M. L. (2020) · International Journal of Endocrinology · doi:10.1155/2020/8877261 · Cited by 2
“To further investigate this last analysis, we then calculated Homeostatic Model Assessment of Insulin Resistance (HOMA IR), a standard measure of insulin resistance, and correlated it with total testosterone.”
BackgroundMethodInfluentialApproach to the Young Male Patient Who Abuses Androgens: Harm Reduction as a Clinical Strategy
Smit, D. L., Verdegaal, T. J., Bond, P., & de Ronde, W. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf496 · Cited by 6
Hormonelle Ursachen des vermehrten Schwitzens
Krützfeldt, J. (2023) · Praxis · doi:10.1024/1661-8157/a004025 · Cited by 2
Cell Biology and Regulation of Adult and Aging Leydig Cell Steroidogenesis
Papadopoulos, V., Garza, S., & Zirkin, B. R. (2025) · Springer eBooks · doi:10.1007/978-3-031-96376-6_4 · Cited by 2
Adlin, E. V. (2020) · Annals of Internal Medicine · doi:10.7326/m19-3815 · Cited by 2
“These guidelines agree fairly closely with guidelines recently proposed by the Endocrine Society (7) and the American Urological Association (8).”
MethodMultiomics unravels the complexity of male obesity: a prospective observational study
Papadakis, G. E., Favre, L., Zouaghi, Y., Vionnet, N., Niederländer, N. J., Adamo, M., Acierno, J. S., Berdous, D., Boizot, A., Meylan, J., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-024-06040-7 · Cited by 3
Costanzo, G., Naselli, A., Arpi, M. L., Piticchio, T., Moli, R. L., Belfiore, A., & Frasca, F. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02270-6 · Cited by 4
“Hypogonadism was defined as the presence in the patient record of serum total testosterone below 320 ng/ dl associated with related symptoms [18] or hormone replace therapy (HRT) for at least 6 months prior to our evaluation.”
Leśniak, K., Lubas, A., & Niemczyk, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082818 · Cited by 3
“Moreover, these formulas have not been validated in patients with advanced kidney disease and on dialysis [18,25].”
InfluentialGonadal and sexual function in men living with HIV: insights from a single-centre study
Bonaventura, I., Hasenmajer, V., D'Addario, N. F., Pozza, C., Ceccarelli, G., d’Ettorre, G., Mastroianni, C. M., Jannini, E. A., & Gianfrilli, D. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02683-5 · Cited by 4
“According to current guidelines, detailed and accu - rate evaluation of pituitary-gonadal axis function in MLWH should therefore require measurement of SHBG along with serum TT and gonadotropins [10 –12 ].”
Craniopharyngioma: Endocrinological Aspects After Surgery
Ilie, M. D., & Raverot, G. (2020) · Springer eBooks · doi:10.1007/978-3-030-41176-3_9 · Cited by 2
Georges, E., Cedarbaum, V., Bisno, D. I., & Marshall, I. (2023) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2022-0521 · Cited by 3
Effect of hormone therapy on personality traits: preliminary evidence in older men and women
Schroeder, R. A., Mordecai, K. L., Resnick, S. M., Terracciano, A., Dobs, A. S., Durso, S. C., Costa, P. T., & Maki, P. M. (2024) · Climacteric · doi:10.1080/13697137.2024.2393128 · Cited by 2
“Similar to HT in older women, TT in older men has mixed effects on cognition [25].”
Bonenti, B., Vigorous, S., Puljević, C., Ferris, J., Barratt, M. J., WINSTOCK, A. R., Ball, L., Armstrong, M., & Piatkowski, T. M. (2025) · American Journal of Lifestyle Medicine · doi:10.1177/15598276251405211 · Cited by 2
“5,42,43 Chi-square tests of independence were conducted to determine whether the prevalence of individual psychosocial concerns, physical concerns, and access dif fi culties differed between age categories.”
InfluentialKuo, Y.-W., Kuo, C., Le, P., Chang, M., Lin, C.-Y., Hsu, C., Lin, W.-P., Chen, C.-W. D., Lin, W.-R., Ho, Y., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13030638 · Cited by 3
“In males, the gold standard for diagnosing hypogonadism is to identify clinical androgen deficiency and confirm it using biochemical testing [22,23].”
Pandit, S. L., Yaligar, D., Halemane, M., & Bhat, A. (2022) · International Journal of Medical Sciences · doi:10.7150/ijms.73645 · Cited by 2
“Testosterone replacement therapy is the primary treatment option for correcting the androgen deficiency in males [30, 31].”
BackgroundJones, R. B., & Snyder, P. J. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.05.008 · Cited by 2
Self-citationShould survivors of childhood cancer or testicular cancer be screened for androgen deficiency?
Rogol, A. D., & Anawalt, B. D. (2018) · Clinical Endocrinology · doi:10.1111/cen.13792 · Cited by 2
Testosterone Deficiency in Hypertensive Men: Prevalence and Associated Factors
Negretto, L. A. F., Rassi, N., Soares, L. R., Saraiva, A. B. C., Teixeira, M. E. F., Santos, L. D. R., Souza, A. L. L., Jardim, P. C. B. V., Barroso, W. K. S., & Jardim, T. V. (2024) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20230138i · Cited by 2
“A TT cut-off of 300ng/dL (12nmol/L) was used to define TD, following the Endocrine Society 1 and the American Urological Association 14 recommendations.”
MethodAndrogenic Anabolic Steroids Cause Thiol Imbalance in the Vascular Endothelial Cells
Ponamarczuk, H., Świątkowska, M., & Popielarski, M. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl26542 · Cited by 5
Dupuis, C., Bachoumas, K., Oris, C., Eisenberg, S., Pereira, B., Boirie, Y., Farigon, N., Sapin, V., Bernard, L., Richard, R., et al. (2025) · Journal of Critical Care · doi:10.1016/j.jcrc.2025.155339 · Cited by 2
Testosterone 2% gel (Testavan®, Testarzon®) in adult male hypogonadism: a profile of its use
Lyseng-Williamson, K. A. (2019) · Drugs & Therapy Perspectives · doi:10.1007/s40267-019-00627-7 · Cited by 2
Park, T. Y., Choi, M., Kim, D. S., Yeo, J. K., Rajasekaran, M. R., & Park, M. G. (2023) · The World Journal of Men s Health · doi:10.5534/wjmh.220274 · Cited by 3
“Therefore, previous TD guidelines did not recommend TT in patients with severe LUTS [23].”
BackgroundSevere Obstructive Sleep Apnea After Pharyngeal Fat Injection for Velopharyngeal Insufficiency
Kazemi, R. J., Turbeville, H. R., & Zopf, D. A. (2025) · The Laryngoscope · doi:10.1002/lary.32234 · Cited by 2
Diabetic Neuropathy: Clinical Management—Genitourinary Dysfunction in Diabetes
Spallone, V., Agrò, E. F., Centello, R., Lecis, C., Orecchia, L., & Isidori, A. M. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-15613-7_28 · Cited by 5
Modern Management of Erectile Dysfunction: An Integrative and Regenerative Therapeutic Framework
Klokol, D., Wong, M. B., Chernykh, V., Iemeliyanova, M., Nishkumai, O., Alvin, G., & Chan, M. K. S. (2026) · SSP Modern Pharmacy and Medicine · doi:10.53933/7z0cx674 · Cited by 3
Sarcopenia in older adults: A narrative review of current concepts in diagnosis and treatment
Güngör, M., & Balcı, C. (2026) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2026.103276 · Cited by 3
Lin, K.-Y., Sun, H., Liu, W.-D., Lin, C.-Y., Tsai, M.-J., Chuang, Y., Li, H., Lin, J., Liu, W., Wu, P., et al. (2024) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2024.05.006 · Cited by 4
Testosterone Replacement Therapy for Testosterone Deficiency in Older Men
McMahon, A. K., & Fantus, R. J. (2025) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2025.01.002 · Cited by 2
Bombardieri, A., Bufano, A., Fralassi, N., Ciuoli, C., Benenati, N., Dalmiglio, C., Voglino, C., Tirone, A., Vuolo, G., & Castagna, M. G. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07426-8 · Cited by 4
“Patients with TT 2.64 ng/ml (or 9.2 nmol/l) were defined as affected by biochemical hypogonadal, according to 2018 American guidelines for male hypogonadism [36].”
MethodInfluentialHormone replacement in disorders of sex development, and long-term effects
Nordenström, A., Mangone, A., & Mantovani, G. (2025) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2025.102022 · Cited by 3
Male hypogonadism and testosterone replacement therapy
Seal, L. (2021) · Medicine · doi:10.1016/j.mpmed.2021.06.002 · Cited by 1
Corona, G., Morgado, L. A. R., Boeri, L., Capogrosso, P., Cocci, A., Dinkelman‐Smit, M., Emmanuel, A., Falcone, M., Jensen, C. F. S., Gül, M., et al. (2026) · European Urology Focus · doi:10.1016/j.euf.2026.04.015 · Cited by 2
Coppola, A., Gallotti, P., Pujia, C., Montalcini, T., Falcone, C., & Gazzaruso, C. (2026) · Hormone and Metabolic Research · doi:10.1055/a-2813-5608 · Cited by 2
Kirby, M. G., Naranjo, A., Ellis, L., & Alaka, M. (2025) · Clinical Oncology · doi:10.1016/j.clon.2025.103778 · Cited by 1
Baik, S. H., Baye, F. M., Fung, K. W., Xian, H., & McDonald, C. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf504 · Cited by 1
Gasco, V., Cuboni, D., Siclari, S., Mocellini, F., Sibilla, M., Grottoli, S., Ghigo, E., & Maccario, M. (2025) · Biomedicines · doi:10.3390/biomedicines13112676 · Cited by 1
“…by a high prevalence of replacement therapy, particularly among men—indirectly supports previous evidence indicating that testosterone replacement mitigates the adverse cardiac effects of hypogonadism [68] and has been reported to correct QTc prolongation in hypogonadal men [58].”
de Velasco, L. M. C., Flores, J. E. G., Kraus-Fischer, G., Arteaga, J. L. M., Casas, M. J. O., Nava, K. N. A., & Morales, F. M. M. (2026) · Cureus · doi:10.7759/cureus.105734 · Cited by 4
“However, testosterone therapy is not indicated for weight loss per se and must be prescribed according to established clinical guidelines in men with confirmed biochemical and clinical evidence of androgen deficiency [19,33].”
Influential
Metadata
- Authors
- Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A.
- Affiliations
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- Baylor College of Medicine (US)
- Massachusetts General Hospital (US)
- University of Southern California (US)
- VA Puget Sound Health Care System (US)
- University of Pennsylvania (US)
- University of California, Los Angeles (US)
- University of Manchester (GB)
- Corresponding author
- Bhasin, Shalender
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2018-03-17
- Volume
- 103
- Issue
- 5
- Pages
- 1715-1744
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2791298691
- Cited by
- 1,736
- References
- 169
- Citations by year
- 2026: 263 · 2025: 196 · 2024: 198 · 2023: 199 · 2022: 240 · 2021: 221 · 2020: 201 · 2019: 157 · 2018: 56
- FWCI
- 126.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- testosterone replacement therapy, male hypogonadism, androgen deficiency, sex hormone-binding globulin, secondary sexual characteristics, treatment monitoring, patient decision-making, pharmacokinetics, sleep apnea, thrombophilia, heart failure, lower urinary tract symptoms, fertility preservation
- MeSH terms
- Aged, Aged, 80 and over, Aging, Blood Chemical Analysis, Diagnostic Techniques, Endocrine, Endocrinology, Humans, Hypogonadism, Male, Middle Aged, Societies, Medical, Testosterone, Evidence-Based Medicine, Hormone Replacement Therapy, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.